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A B S T R A C T
BACkgRound: Despite significant advances in the management of coronary heart 
disease, myocardial infarction is still associated with high mortality. Thienopyridines 
and glycoprotein IIb/IIIa inhibitors have been used extensively in the management of 
ST segment elevation myocardial infarction. 
oBjeCTive: This article discusses the evidence from clinical trials and registries con-
cerning the benefits of thienopyridines, reviews the results of published multicenter, 
randomized controlled trials of the efficacy and safety of platelet GPIIb/IIIa inhibi-
tors in patients with acute myocardial infarction undergoing primary percutaneous 
coronary intervention (PCI) and presents the recent guidelines.
MeThodS: Data for this review were identified by broad searches of MEDLINE, Cur-
rent Contents and references from relevant articles (1980-2011); numerous articles 
were identified through searches of the extensive files of the authors and selected 
based on their importance, opportunity for further reading and up to date informa-
tion. Search terms included thienopyridines, platelet aggregation inhibitors, percuta-
neous coronary intervention, antiplatelet therapy, ST elevation myocardial infarction 
(STEMI), primary percutaneous coronary intervention. Only English language pa-
pers were reviewed. No restrictions were set on the type of papers.
ReSulTS: Clopidogrel is the most commonly used thienopyridine in patients under-
going primary PCI. Recently new inhibitors of P2Y12 receptors, like prasugrel and 
ticagrelor, have become available, which have a more potent and rapid onset of action, 
with similar safety profile, which is specifically targeted to the subgroup of primary 
PCI. On the other hand, the platelet glycoprotein IIb/IIIa inhibitors have aided and 
abetted medical management of acute coronary syndromes and proved an important 
adjunctive therapy in percutaneous coronary interventions. Platelet glycoprotein IIb/
IIIa inhibitors, although not recommended for routine therapy, have an important 
role at the time of primary PCI, particularly in high-risk subgroups, like the diabetics 
and those with a heavy thrombotic burden.
ConCluSion: Clopidogrel remains the most used thienopyridine together with aspi-
rin in patients undergoing primary PCI but there are currently available new inhibi-
tors of P2Y12 receptors, like prasugrel and ticagrelor, which have a more potent and 
rapid onset of action, with similar safety profile. Glycoprotein IIb/IIIa antagonists, 
although not recommended for routine therapy, can be of use at the time of primary 
PCI, particularly in high-risk subgroups.
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i n T R o d u C T i o n
Prompt restoration of blood flow in the infarcted coro-
nary artery and subsequent myocardial tissue reperfusion 
are fundamental in the treatment of ST-elevation myocardial 
infarction (STEMI).1 Irrespectively of how restoration of blood 
flow is achieved - mechanically or pharmaceutically - addition 
of dual antiplatelet regimen reduces mortality and the rate 
of recurrent ischemic events.2,3 This is mainly attributed to 
the primary role of platelets in the activation of hemostasis, 
when the atherosclerotic plaque ruptures and the vascular 
endothelium is denuded.4 Apart from the well established 
use of aspirin, other molecular targets of drug therapy on the 
activated platelet include the adenosine diphosphate (ADP) 
P2Y12 receptors and the glycoprotein IIb-IIIa (GPIIB-IIIA) 
receptors, which take part in platelet binding with fibrinogen 
or von Willebrand’s factor.5 This review focuses on the use of 
P2Y12 and GPIIB-IIIA receptor inhibitors in the manage-
ment of STEMI, treated with primary percutaneous coronary 
intervention (PPCI). 
A d P  P 2 y 1 2  R e C e P T o R  i n h i B i T o R S 
There are three thienopyridines and a nucleoside ana-
logue that inhibit the ADP P2Y12 receptors in clinical use; 
ticlodipine, clopidogrel, prasugrel and ticagrelor. Ticlodipine 
has been almost abandoned because of side-effects, including 
hemorrhagic diathesis, leucopenia, thrombocytopenia, aplastic 
anemia and Moskowitz syndrome.6 Hence, clopidogrel and 
prasugrel that present a safer profile remain of option, while 
most recently ticagrelor has also become available. The site of 
action of the P2Y12 inhibitors is shown in Figure 1.
Clopidogrel
Clopidogrel is an oral, irreversible inhibitor of ADP P2Y12 
receptors on the platelet surface. Following absorption of a 
large proportion from the intestine, it follows two pathways of 
metabolism. The first is related to the conversion of the 85% 
of the clopidogrel intake to an inactive metabolite by esterases 
in the intestine, portal circulation and the liver. The remain-
ing 15% is metabolized in a two-step process at the level of 
hepatic CYP-450.7 The final result is the presence of only 2% 
of the total clopidogrel intake on the specific platelet receptors.
Even though clopidogrel administration is recommended 
as soon as possible before or during PPCI, exact timing of 
use has not been yet established by any large randomized 
trial (class of recommendation, level of evidence IC).1,8 In 
the COMMIT/CCS 2 trial (Clopidogrel and Metoprolol in 
Myocardial Infarction Trial/Second Chinese Cardiac Study), 
Chen et al2 observed a reduction of the relative risk of death 
FiguRe 1. Molecular targets of drug therapy on the activated platelet. 
CYP: Cytochrome P-450; P2Y12: Purinergic receptor P2Y, G-protein coupled, 12; GP IIb/IIIa: glycoprotein IIb/IIIa
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by 7% during the scheduled treatment period in hospital 
(mean 15 days), in patients who had not undergone PPCI, 
after adding clopidogrel 75 mg per day to the aspirin regimen. 
Sabatine et al 3 also found a 20% reduction of the relative risk 
of cardiovascular death, recurrent ischemic events or urgent 
revascularization, in a 30-day follow up, using a 300 mg clopi-
dogrel loading dose followed by 75 mg daily on top of aspirin 
administration, in STEMI patients who underwent angioplasty 
in a median of three days after thrombolysis. Additionally, 
results from registries support the use of clopidogrel, either 
pre-, or post- revascularization.9,10 
Nonetheless, a wide range of patients’ response to clopi-
dogrel’s action exists. Response to clopidogrel shows a normal 
distribution following 300 mg loading and 75 mg/day dose, with 
31% of patients being resistant to its action, 24 hours and 5 
days after its administration.11 Similarly, the rate of clopidogrel 
resistance approaches 20%, the latter being associated with 
higher rates of stent thrombosis.12 In a recent meta-analysis, 
analyzing both acute and stable patients with coronary artery 
disease, clopidogrel resistance was followed by a higher risk 
of death or ischemic events.13 
Clopidogrel resistance is multifactorial, with genetic 
and clinical factors being implicated in its pathogenesis. 
CYP2C19*2 loss-of-function polymorphism seems to be 
associated with high platelet reactivity despite clopidogrel 
administration.14 Age >70 years, obesity and diabetes mellitus 
have similarly an adverse impact on platelet reactivity.14,15 How-
ever, all of the above mentioned factors cannot explain more 
than 11.5% of clopidogrel low responsiveness.14 Furthermore, 
clopidogrel resistance could be enhanced due to low dosing or 
drug-drug interaction, especially when co-administered with 
proton pump inhibitors.16 In contrast, the COGENT study 
(Clopidogrel and the Optimization of Gastrointestinal Events 
Trial)17 not only did not support the drug-drug interaction 
theory between clopidogrel and omeprazole, but found that the 
omeprazole group had lower rate of gastrointestinal bleeding. 
Finally, the drug’s absorption from the gut seems to be 
affected in states of stress, such as STEMI, due to reduced 
perfusion, activation of the sympathetic nervous system and 
release of atrial natriuretic peptide that inhibits gut perme-
ability.18-20 In addition to the extremely augmented platelet 
activation,21 patients suffering from STEMI absorbed less 
clopidogrel and achieved maximum drug concentration in 
blood later than healthy controls.22 The latter is independent 
of CYP3A4 and CYP3A5 activity, as the conversion rate of 
clopidogrel to its active metabolite remained unchanged in 
both groups. These facts resulted in an inadequate inhibition 
of platelet reactivity, even 24 hours after drug administration, 
due to its impaired bioavailability.
A number of pharmacological studies have been conducted 
in order to investigate clopidogrel resistance and its dose de-
pendence. According to the ISAR-CHOICE study (Intracoro-
nary Stenting and Antithrombotic Regimen: Choose Between 
3 High Oral Doses for Immediate Clopidogrel Effect), clopi-
dogrel loading dose of 600 mg achieved significantly greater 
platelet inhibition 4 hours later, compared to the loading dose 
of 300 mg, in patients with coronary artery disease.23 On the 
contrary, a dose of 900 mg did not show further inhibition, 
possibly due to limited clopidogrel absorption.23,24 Usage of 
the enhanced loading dose of 600 mg is critical in states with 
increased thrombotic burden, such as STEMI. Matetzky et al 
reloaded a low clopidogrel response group of patients, suffer-
ing an acute myocardial infarction (15% of total population), 
who were initially administered 300 mg of clopidogrel, with 
600 mg clopidogrel, followed by 150 mg daily dose. Of note, 
the clopidogrel responders were under the classic regimen 
of 300 mg/75 mg).25 The study resulted in a great decrease of 
platelet reactivity in just 4 hours after reloading, remaining low 
as long as double dose of clopidogrel was administered. An ad-
ditional interesting observation of this study was that patients 
presenting with STEMI were more likely to be nonresponders 
to clopidogrel (90% vs 74%, p = 0.06).
The large, multicenter study CURRENT-OASIS 7 (Clopi-
dogrel Optimal Loading Dose Usage to Reduce Recurrent 
Events/Optimal Antiplatelet Strategy for Interventions),26 
compared double dose of clopidogrel (600 mg loading/150 mg 
daily for the next 6 days /75 mg daily thereafter) with stand-
ard dose (300 mg loading/75 mg daily), in patients with acute 
coronary syndromes, and the clinical outcome at 30 days was 
evaluated. The results referring to the overall population not 
only did not show any clinical value of the double dose, but 
an increase of major bleeding rate was observed.27 Interest-
ingly, in the subgroup undergoing PPCI because of STEMI 
(7327 patients), higher clopidogrel dose significantly reduced 
stent thrombosis and myocardial infarction rates, without any 
increase of bleeding events. In the HORIZONS-AMI trial 
(Harmonizing Outcomes With Revascularization and Stents 
in Acute Myocardial Infarction), the impact of clopidogrel 
loading 600 mg versus 300 mg on the 30- day clinical outcomes 
was evaluated in patients suffering a STEMI, undergoing PPCI 
and assigned either in unfractionated heparine plus glycopro-
tein IIb-IIIa inhibitors or bivalirudin monotherapy. A 600-mg 
compared with a 300-mg loading dose of clopidogrel was 
associated with lower 30-day rates of mortality, reinfarction, 
and stent thrombosis, without any association with increased 
rates of bleeding.28 
Regarding the timing of loading dose administration, 
Vlaar et al29 studied the effects of clopidogrel when given 
pre- or post- initial angiography. This meta-analysis included 
patients who underwent PPCI following STEMI. The group 
of early, pre-PCI clopidogrel administration showed better 
patency angiographically (TIMI flow 2-3), and significantly 
lower rate of clinical outcome of death or death and recur-
rent infarction compared to those in whom clopidogrel was 
administered after PCI.
Following the above data, the 2011 American College of 
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Cardiology (ACC) and American Heart Association (AHA), 
as well as European Society of Cardiology (ESC) guidelines 
on myocardial revascularization recommend administration 
of 600 mg of clopidogrel in every STEMI patient scheduled 
for PCI, as soon as possible, followed by 75 mg daily (rec-
ommendation IC and IB in ESC and ACC/AHA guidelines 
respectively).8,30
Prasugrel
Prasugrel is a novel, 10 times more potent than clopidogrel, 
thienopyridine anti-platelet agent. Similar to clopidogrel, pras-
ugrel is extensively hydrolyzed by intestinal plasma esterases to 
an inactive terminal metabolite, with the residual unhydrolized 
drug metabolized in a single step (instead of two in the case 
of clopidogrel) to the active sulfhydryl compound, mainly by 
cytochrome P450 3A4 (CYP3A4) and 2B6 (CYP2B6) enzymes. 
As a result, about 80% of an orally absorbed dose of prasugrel 
is converted to active drug, compared with only 10% to 20% of 
absorbed clopidogrel. Finally, the active metabolite irreversibly 
connects and inhibits the platelet receptors ADP P2Y12.31,32 
Brandt’s pharmacodynamic study,33 in healthy volunteers, 
showed that 60 mg of prasugrel, compared to 300 mg of 
clopidogrel, achieved greater and faster platelet inhibition, 
in just 15 minutes from its administration, maintaining its ac-
tion during the whole 24 hours of study time. Jernberg et al 
reached the same results for prasugrel loading dose either 60 
mg or 40 mg and this enhanced action was retained with daily 
dose of 10 or 15 mg of prasugrel when compared with 75 mg of 
clopidogrel.34 In another pharmacodynamic study, conducted 
by Varenhorst, 35 60 mg of prasugrel had a more potent action 
even than 600 mg of clopidogrel, which actually remained even 
with the daily dose (10 mg prasugrel versus 75 mg clopidogrel). 
Finally, switching from maintenance clopidogrel to prasugrel 
offers further platelet inhibition in just 2 hours from a loading 
dose of 60 mg or in 7 days if the loading dose is omitted and 
10 mg/day are used.36 
Contrary to clopidogrel, neither specific genetic traits 
nor pharmacokinetic drug interactions seem to interfere with 
prasugrel antiplatelet activity. As opposed to clopidogrel, 
administered prasugrel is practically completely activated. 
Even though, at first sight with a similar two-step process, this 
activation shows distinct differences. The first metabolic step 
is mediated by carboxylesterases and the second reaction is 
catalyzed by five different CYP isoenzymes, with no pivotal 
role for CYP 2C19 or any other CYP isoform. Unfolding evi-
dence, including a lack of interference by genotype and CYP 
2C19 or CYP 3A4 inhibitors, has confirmed this expectation.37
The greater and faster platelet inhibition has been trans-
lated into clinical benefit.38,39 Administration of prasugrel in 
STEMI patients (3534 patients, 69% PPCI) in the TRITON-
TIMI 38 trial (Trials to Assess Improvement in Therapeutic 
Outcomes by Optimizing Platelet Inhibition with Prasugrel–
Thrombolysis in Myocardial Infarction) reduced the primary 
endpoint (death, myocardial infarction, stroke) after 30 days 
and kept it low until the 15th month, compared to that of 
clopidogrel group.39 The stent thrombosis rate was also 
lowered (p=0.0084), whilst it was observed that the anterior 
myocardial infarction subgroup was particularly favoured by 
the use of prasugrel. Bleeding event rate has not shown any 
increase, apart from the patients who underwent coronary 
artery bypass grafting (CABG). The prasugrel group exhibited 
increased risk of TIMI major bleeding after CABG. Overall, 
major, minor, intracranial and life-threatening bleeding event 
rates were similar in both groups. Thus, with regards to net 
clinical outcome, prasugrel administration is beneficial in 
STEMI patients, while in the overall population of the trial, 
mortality did not differ significantly between treatment groups. 
Of note, until now there exists no direct comparison assessing 
clinical endpoints between 600 mg/150 mg of clopidogrel and 
60 mg/10 mg of prasugrel.
Prompt administration of 60 mg of prasugrel following 
STEMI, and its continuation with 10 mg daily, has recently 
received a IB recommendation when STEMI is managed with 
PPCI by both the European Society of Cardiology (ESC) and 
the American Heart Association (AHA).8,30 The STEMI sub-
group, in the TRITON-TIMI 38 study,39 did not appear to be 
at higher risk of major bleeding, irrespectively of the patients’ 
demographics. The contraindications of prasugrel usage, i.e. 
history of stroke / transient ischemic attack and special precau-
tions for its use (age ≥75 or weight <60 kg) remain valid, as 
arose from the overall trial population.38 
Ticagrelor
Ticagrelor is a new oral inhibitor of P2Y12 platelet recep-
tor. This new agent competes with ADP, reversibly binding 
to target receptor. Contrary to regimens described above, 
ticagrelor does not require metabolic activation and directly 
acts on its receptor.40
The recent ONSET-OFFSET study has revealed that 
ticagrelor (180 mg loading dose/90 mg bid maintenance dose) 
inhibits platelet aggregation much stronger and faster than 
clopidogrel (600 mg/75 mg). Interestingly, following discon-
tinuation of treatment, platelet reactivity was restored faster 
in the ticagrelor group.41
Ticagrelor’s properties make it ideal in situations of great 
thrombogenicity, like STEMI, irrespective of whether angio-
plasty is performed or CABG is recommended. In the PLATO 
(Platelet Inhibition and Patient Outcomes) trial (18624 pa-
tients with acute coronary syndrome), ticagrelor reduced the 
primary endpoint (death from vascular causes, myocardial 
infarction or stroke) by 16% compared to clopidogrel.42 These 
results were achieved without any compromise in drug’s safety 
profile, if minor bleeding events are excluded. In the STEMI 
subgroup (7544 patients, 1.3 hours delay from admission to 
PCI), being managed with PPCI, the results remained the 
same with those of the main study.43 Ticagrelor’s impressive 
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outcomes are attributed, apart from the strong, reversible 
platelet inhibition, to the inhibition of adenosine reuptake 
from red cells, that improves myocardial microcirculation44 
and, possibly, suggestive of a pleiotropic action.45
In 2010, ticagrelor (180 mg loading dose/90 mg bid main-
tenance dose) received a recommendation of IB for STEMI 
management, when combined with PPCI, according to the 
ESC guidelines on myocardial revascularization.30 Recently, 
USA Food and Drug Administration (FDA) approved its use 
that was pending due to its non-efficacy in the North America 
subgroup (hazard ratio-HR 1.25; confidence intervals- CI 
(0.93, 1.67), p=0.05).42 Following the latter development, 
late in 2011, AHA also recommended (Class IB) the use of 
ticagrelor in STEMI patients.8
Conclusion
To sum up, it appears that clopidogrel may not be the only 
antiplatelet agent of choice in the management of STEMI. 
In a recent meta-analysis, Bellemain et al compared newer 
inhibitors of P2Y12 receptors with clopidogrel in patients 
that had undergone PCI.46 In the STEMI subgroup, newer 
agents exhibit reduced mortality, without any significant 
change in major bleeding incidents. The increased thrombotic 
state encountered in STEMI makes these new, more potent 
agents, even more effective than clopidogrel. In parallel, this 
thrombogenicity contributes to the safety of the increased 
platelet inhibition that newer agents achieve.46 It seems that 
new established agents like prasugrel and ticagrelor, as well 
as, other under trial inhibitors of P2Y12 receptors,47,48 have 
much to contribute in the antiplatelet management of the 
STEMI patient in the near future. A synopsis of the use of 
P2Y12 inhibitors in PPCI is shown in Table 1.
g ly C o P R o T e i n  i i B / i i i A  R e C e P T o R S 
i n h i B i T o R S
The intravenously administrated glycoprotein IIb/IIIa 
inhibitors (GPIIb/IIIa), abciximab, tirofiban, and eptifibatide, 
have a principal role in the adjunctive pharmacotherapy of 
STEMI because they seem to improve tissue-level reperfu-
sion, restoration of blood flow in the infarct-related artery 
and improve the impaired left ventricular function.49 The site 
of action of IIb/IIIa inhibitors is shown in Figure 1.
A key issue with the use of GPIIb/IIIa inhibitors is whether 
they can improve the prognosis of patients with STEMI who 
are managed with PPCI.50,51 A meta-analysis of 11 randomized 
trials, involving 27115 patients, showed a significant reduction 
in short-term (30 days) mortality (2.4% vs. 3.4%, p=0.047) and 
long-term (6-12 months) mortality (4.4% vs. 6.2%, p=0.01) 
in patients treated with abciximab when compared with a 
control group. Abciximab resulted in a significant reduction 
in 30-day reinfarction rate (1.0% vs. 1.9%, p=0.03) but also 
in an increased risk of major bleeding complications (4.7% 
TABle 1. P2Y12 Receptor Inhibitors in Primary Percutaneous Coronary Intervention (PCI)
Study Population Study design Primary end-Points
CURRENT OASIS 7 
201026
Patients with STEMI 
mostly treated with 
primary PCI
N= 6346
2x2 factorial design, double dose 
clopidogrel vs standard dose and 
either higher or lower dose aspirin
Cardiovascular death, MI, stroke at 30 
days
HORIZONS AMI 200928 Patients with STEMI 
undergoing PCI
N= 3602
Randomization to bivalirudin 
or unfractionated heparin plus 
glycoprotein IIb-IIa inhibitors, 
stratified by clopidogrel loading 
dose (600 mg vs 300 mg)
Major bleeding and combined adverse 
clinical events, defined as the combination 
of major bleeding or major adverse 
cardiovascular events including death, 
reinfarction, target-vessel revascularization 
for ischemia, and stroke within 30 days.
TRITON-TIMI 38 200939 Patients with STEMI
N= 3534
Assigned either prasugrel (60 mg 
LD/ 10 mg MD) or clopidogrel 
(300 mg LD/75 mg MD)
Cardiovascular death, non-fatal myocardial 
infarction, or non-fatal stroke in the 
following 15 months
PLATO STEMI subgroup 
analysis 201043
Acute coronary 
syndrome patients with 
STEMI or left bundle 
branch block
N= 7544
Randomized, double blind 
trial, comparing ticagrelor (180 
mg LD/90 mg bid MD) with 
clopidogrel (300 mg LD/75mg 
MD)
Composite of death from vascular causes, 
myocardial infarction, or stroke at 12 
months
LD = loading dose; MD = maintenance dose; MI = myocardial infarction; STEMI = ST elevation myocardial infarction
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vs. 4.1%, p=0.36).50,52 In another meta-analysis including 3266 
patients with acute myocardial infarction, the early reduc-
tion in ischemic events was partly balanced by an increased 
likelihood of major bleeding with abciximab therapy (odds 
ratio-OR, 0.73; 95% confidence intervals-CI, 1.11-2.72). In 
that sense, benefits of abciximab must be balanced against 
the bleeding risk in individual patients, and attention must be 
paid to appropriate dosing of antithrombin therapies.53-57 It is 
important to mention that in the above meta-analysis, patients 
did not receive clopidogrel loading before PCI. Therefore, a 
logical question arises whether abciximab has a benefit for 
PPCI patients who received loading with clopidogrel. This 
was tested in the 800 patients of the Bavarian Reperfusion 
Alternatives Evaluation (BRAVE)-3 trial, pre-treated with 
600 mg of clopidogrel, whereby abciximab was not associated 
with a reduction in infarct size and no clinical benefit at 30 
days and at 1 year was observed. There was a trend towards 
a benefit with abciximab in patients who were enrolled <180 
min from the onset of symptoms.58 
The Ongoing Tirofiban in Myocardial Evaluation (ON-
TIME) 2 trial59 assessed whether pre-hospital initiation 
of tirofiban in patients with STEMI undergoing PPCI has 
beneficial results in addition to dual antiplatelet therapy.60,61 
Results of the double-blind phase noted that at 1 hour post-
PCI, the rate of residual ST-segment deviation (>3 mm) was 
significantly reduced (43.3% vs. 36.0%, p=0.02) and lower 
rate TIMI flow 0/1 or distal embolisation after PCI (6.2% vs. 
10.3%, p=0.029) was observed with tirofiban. At 30 days, the 
combined rate of death, recurrent myocardial infarction, or 
major adverse cardiac events (MACE) was significantly lower 
in the tirofiban arm (5.8% vs. 8.6%, p=0.043). There was a 
strong trend towards a significant decrease in mortality with 
tirofiban with respect to all-cause mortality (2.2% vs. 4.1%, 
p=0.051). Patients who presented early after symptom onset 
(≤75 min) demonstrated a significant reduction in MACE 
with tirofiban therapy (4.3% vs. 8.1%). The clinical benefit 
was sustained at 1 year since a post hoc analysis indicated a 
significantly lower mortality with tirofiban therapy (2.4% vs. 
5.5%, p=0.007) and a significantly lower occurrence of stroke 
(0.3% vs. 1.4, p=0.031).61 In the ON-TIME 2 study the median 
time from the onset of symptoms until the initiation of tirofiban 
was only 90 min, while in the BRAVE-3 study the abciximab 
was started rather late (>200 min) after the onset of symptoms. 
Early administration of GPIIb/IIIa inhibitors seems to have 
clear advantage, compared with delayed administration, as 
it improves the clinical outcome of patients who have been 
preloaded with high-dose clopidogrel (600 mg) in addition 
to aspirin and unfractionated heparin after PPCI with no in-
creased risk of major bleeding. In contrast, in the Safety and 
Efficacy Study of Integrillin-Facilitated PCI Versus PPCI in 
STEMI (ASSIST), there was no difference between heparin 
plus eptifibatide vs heparin alone in patients referred for PPCI. 
At 30 days, the primary end point - the composite of death from 
any cause, recurrent myocardial infarction, or recurrent severe 
ischemia – was 6.47% in the heparin plus eptifibatide group, 
and 5.53% in the heparin-alone group (p=0.69). Similarly, 
at 6 months, there was no difference in the incidence of the 
primary end point between the two groups (7.96% vs. 7.11%, 
p=0.75). However, the rates of bleeding (major or minor) 
were significantly higher in patients assigned to heparin plus 
eptifibatide (22.4% vs. 14.6%, p=0.04).62 
An important factor that determines the benefit from 
administration of GPIIb/IIIa inhibitors seems to be the basic 
risk of each patient. There is a linear relationship between the 
baseline risk of the patient cohort and the effects of GPIIb/
IIIa on mortality. Particularly, the higher patients’ mortality 
who received placebo or bivalirudin, the higher the reduction 
in mortality achieved from the GPIIb/IIIa inhibitors admin-
istration.63 
Another important question concerns the timing that is 
better to administer the GPIIb/IIIa inhibitor in the ambulance 
or in the catheterization laboratory. In the Facilitated Inter-
vention with Enhanced Reperfusion Speed to Stop Events 
(FINESSE) study neither facilitation of PCI with reteplase plus 
abciximab nor facilitation with abciximab alone significantly 
improved the clinical outcomes, as compared with abciximab 
given at the time of PCI.64 In a post hoc analysis of the FI-
NESSE study, patients with TIMI risk score ≥3 and presenta-
tion to a spoke site with a symptom-to-randomization time 
≤4 hours had a significantly better 1-year survival if treated 
with combination-facilitated PCI (hazard ratio [HR]: 0.0351, 
p=0.01) as well as 90-day composite outcome (HR:0.45, 
p=0.009).65
In the EUROTRANSFER Registry, 1650 patients were 
randomized to receive abciximab, either before admission to 
the catheterization laboratory, immediately before or during 
PCI in the catheterization laboratory. Analysis according to 
the risk profile showed significant difference only in high-risk 
patients. Particularly 1-year mortality was significantly lower 
with early abciximab administration compared to late admin-
istration (8.7% vs. 15.8%, p=0.01) at 1-year follow-up. Early 
abciximab administration strategy did not result in a significant 
increase in bleeding rate and provided a better benefit to harm 
profile than standard therapy in high-risk patients.66
In the MISSION study, patients who received abciximab 
in the ambulance, within a median time of 63 min (golden 
period) from the onset of symptoms, presented higher infarct-
related artery patency at the onset of the PCI compared to the 
in-hospital group (odds ratio=4.9; 95% CI 2.4-10.1), smaller 
infarct size, higher left ventricular function at 90 days post-
PPCI (59% vs. 54%, p=0.01), and lower incidence of heart 
failure through a median of 210 days of clinical follow-up (3% 
vs.11%. p=0.04).67
Another important question is whether all GPIIb/IIIa 
inhibitors (abciximab, eptifibatide, tirofiban) offer the same 
benefit to the patient for whom PPCI is planned. In the Ep-
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tifibatide Versus Abciximab in PPCI for Acute Myocardial 
Infarction (EVA-AMI) trial, the incidence of complete ST 
segment resolution (STR) at 60 min after PCI was 62.6% after 
eptifibatide and 56.3% after abciximab. All-cause mortality was 
6.2% vs 4.5% (p=0.50), reinfarction 0.4% vs.3.5% (p=0.03), 
target vessel revascularization 4.4% vs. 6.5% (p=0.40) and 
the combined end-point of death, nonfatal reinfarction, and 
target vessel revascularization 10.6% vs. 10.9% (p=0.90).68 
The Swedish Coronary Angiography and Angioplasty Reg-
istry (SCAAR) suggested that eptifibatide is non-inferior to 
abciximab in 11479 patients with STEMI undergoing PPCI 
with an odds ratio 0.94 (95% CI: 0.82 to 1.09) and this non-
inferiority was also shown at the secondary end points of death 
and myocardial infarction separately with odds ratio 0.99 (95% 
CI: 0.82 to 1.19) and 0.88 (95% CI: 0.73 to 1.05), respectively.69 
The MULTISTRATEGY trial compared the effect of high-
dose bolus tirofiban (25 μg/Kg) with abciximab infusion in 
745 patients with STEMI undergoing PCI. At 30 days, the 
incidence of the primary clinical end point- a composite of 
death, reinfarction, or revascularization of the target vessel- 
was 4.3% vs. 4.0% (p=0.85) in the abciximab and tirofiban 
groups respectively, while the incidence of major and minor 
TABle 2. GPIIb/IIIa Receptor Inhibitors in Primary Percutaneous Coronary Intervention
Study Population Study design Primary end-Points
MULTISTRATEGY 
200866
Patients with STEMI or new 
LBBB undergoing PCI
N= 745
Open –label, 2x2 factorial 
trial, high dose bolus tirofiban 
vs abciximab infusion
8-month combined death from any cause, 
reinfarction, and clinically driven target-vessel 
revascularization
ON-TIME 2 200855 Patients with STEMI 
scheduled for PCI
N= 984
Randomized double blind 
high bolus tirofiban vs 
placebo
The extent of residual ST-segment deviation 
1hour after PCI
BRAVE-3 200954 Patients with acute MI 
presenting <24 h after the 
onset of symptoms
N= 1285
Randomized double-blind 
trial, abciximab vs placebo 
group
Infarct size in the single –photon emission 
computed tomography
ASSIST 200958 Patients with STEMI 
referred for primary PCI
N=414
Randomized trial, 
heparin+eptifibatide vs 
heparin alone
Composite death from any cause, recurrent 
myocardial infarction, or recurrent severe 
ischemia during the first 30 days after 
randomization
FINESSE 200961 Patients who presented 
within 6h of the onset of 
STEMI stratified by TIMI 
risk score
N=2452
Randomized double 
blind trial, half dose 
reteplase+abciximab vs 
abciximab alone vs placebo
Composite of all-cause mortality, 
ventricular fibrillation occurring >48 h 
after randomization, cardiogenic shock, and 
congestive heart failure requiring hospital stay 
or emergency department visit within 90 days
EUROTRANSFER 
200962
Patients with STEMI who 
were scheduled for primary 
PCI
N =1650
Not randomized registry, 
abciximab early vs abciximab 
late
Composite of all cause death, reinfarction and 
bleeding complications at 30 days after PCI
EVA-AMI 201064 Patients with STEMI and 
planned primary PCI
N=427
Randomized open parallel 
group study, double-bolus 
eptifibatide vs single-bolus 
abciximab
Incidence of complete ST-segment resolution 
60 min after PCI
SCAAR 201065 Patients with STEMI who 
underwent primary PCI
N=11479
Not randomized registry,
eptifibatide vs abciximab
Death or myocardial infarction during 1-year 
follow-up
LBBB = left bundle branch block; MI = myocardial infarction; PCI = percutaneous coronary intervention; STEMI = ST elevation myocardial 
infarction
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bleedings did not differ (7.8% in the abciximab vs 7.2 in the 
tirofiban group, p=0.89).70
The more recent guidelines for STEMI patients of the 
American College of the Cardiology Foundation/American 
Heart Association (2011) suggest that it is reasonable to start 
treatment with a GPIIb/IIIa receptor antagonist at the time 
of PPCI (with or without stenting) in selected patients with 
STEMI (class IIa), while the usefulness of these agents before 
the arrival of patients in the cardiac catheterization laboratory 
is uncertain (class IIb).8 The ESC/European Association of 
Cardiothoracic Surgery (EACTS) guidelines (2010) suggest 
that an indication for GPIIb/IIIa administration have all the 
patients with STEMI undergoing PPCI and present high 
intracoronary thrombus burden. Particularly, abciximab and 
eptifibatide are class IIa, while tirofiban is class IIb. Finally, the 
administration of these agents before patients’ arrival in the 
catheterization laboratory is not considered beneficial (class 
III).71 A synopsis of the use of IIb/IIIa inhibitors in PPCI is 
presented in Table 2.
C o n C l u S i o n
The ADP P2Y12 receptor inhibitors have been proven to 
be beneficial in reducing mortality in patients suffering from 
STEMI. Newer antiplatelet agents, such as prasugrel and 
ticagrelor, seem to offer greater efficacy than clopidogrel, 
with comparable safety, especially when combined with PPCI. 
In addition, GPIIb/IIIa antagonists can be of use at the time 
of PPCI but are not recommended as routine therapy. Many 
times the benefit of these agents depends on the timing of 
administration and patients’ risk profile. Patients with the high-
est ischemic risk seem to have the highest benefit from these 
agents, while they offer comparable benefit in PPCI patients.
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